HighTower Advisors
CASI

HighTower Advisors’s CASI Pharmaceuticals CASI Stock Holding History

HighTower Advisors’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,357
Closed -$11K – 3274
2022
Q1 		$11K Hold
1,357
– – ﹤0.01% 3208
2021
Q4 		$10K Buy
1,357
+355
+35% +$3.54K ﹤0.01% 3154
2021
Q3 		$12K Buy
+1,002
New +$13.6K ﹤0.01% 3026

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HighTower Advisors's CASI Position: Q2 2022 in Review

HighTower Advisors sold out of CASI Pharmaceuticals (CASI) in Q2 2022, closing a stake of 1,357 shares — an estimated $11K sold.

HighTower Advisors first reported a position in CASI in Q3 2021 and held it in 3 quarters. The position peaked at $12K in Q3 2021. 24 funds tracked by Wall St. Rank hold CASI as of Q2 2022.

  • HighTower Advisors reported no remaining CASI Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • HighTower Advisors sold 1,357 CASI Pharmaceuticals shares in Q2 2022, an estimated $11K.
  • HighTower Advisors first reported a position in CASI Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • HighTower Advisors's CASI Pharmaceuticals position peaked at $12K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2022.

Based on HighTower Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.